BACKGROUND: After a decade of war in Iraq and Afghanistan, we have observed an increase in combat-related injury survival and a paradoxical increase in injury severity, mainly because of the effects of blasts. These severe injuries have a devastating effect on each patient's immune system resulting in massive upregulation of the systemic inflammatory response. By examining inflammatory mediators, preliminary data suggest that it may be possible to correlate complications such as wound failure and heterotopic ossification (HO) with distinct systemic and local inflammatory profiles, but this is a relatively new topic. QUESTIONS/PURPOSES: We asked whether systemic or local markers of inflammation could be used as an objective means, independent of demographic and subjective factors, to estimate the likelihood of (1) HO and/or (2) wound failure (defined as wounds requiring surgical débridement after definitive closure, or wounds that were not closed or covered within 21 days of injury) in patients sustaining combat wounds. METHODS: Two hundred combat wounded active-duty service members who sustained high-energy extremity injuries were prospectively enrolled between 2008 and 2012. Of these 200 patients, 189 had adequate followups to determine the presence or absence of HO, and 191 had adequate followups to determine the presence or absence of wound failure. In addition to injury-specific and demographic data, we quantified 24 cytokines and chemokines during each débridement. Patients were followed clinically for 6 weeks, and radiographs were obtained 3 months after definitive wound closure. Associations were investigated between these markers and wound failure or HO, while controlling for known confounders. RESULTS: The presence of an amputation (p < 0.001; odds ratio [OR], 6.1; 95% CI. 1.63-27.2), Injury Severity Score (p = 0.002; OR, 33.2; 95% CI, 4.2-413), wound surface area (p = 0.001; OR, 1.01; 95% CI, 1.002-1.009), serum interleukin (IL)-3 (p = 0.002; OR, 2.41; 95% CI, 1.5-4.5), serum IL-12p70 (p = 0.01; OR, 0.49; 95% CI, 0.27-0.81), effluent IL-3 (p = 0.02; OR, 1.75; 95% CI, 1.2-2.9), and effluent IL-13 (p = 0.006; OR, 0.67; 95% CI, 0.50-0.87) were independently associated with HO formation. Injury Severity Score (p = 0.05; OR, 18; 95% CI, 5.1-87), wound surface area (p = 0.05; OR, 28.7; 95% CI, 1.5-1250), serum procalcitonin ([ProCT] (p = 0.03; OR, 1596; 95% CI, 5.1-1,758,613) and effluent IL-6 (p = 0.02; OR, 83; 95% CI, 2.5-5820) were independently associated with wound failure. CONCLUSIONS: We identified associations between patients' systemic and local inflammatory responses and wound-specific complications such as HO and wound failure. However, future efforts to model these data must account for their complex, time dependent, and nonlinear nature. LEVEL OF EVIDENCE: Level II, prognostic study. See the Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: After a decade of war in Iraq and Afghanistan, we have observed an increase in combat-related injury survival and a paradoxical increase in injury severity, mainly because of the effects of blasts. These severe injuries have a devastating effect on each patient's immune system resulting in massive upregulation of the systemic inflammatory response. By examining inflammatory mediators, preliminary data suggest that it may be possible to correlate complications such as wound failure and heterotopic ossification (HO) with distinct systemic and local inflammatory profiles, but this is a relatively new topic. QUESTIONS/PURPOSES: We asked whether systemic or local markers of inflammation could be used as an objective means, independent of demographic and subjective factors, to estimate the likelihood of (1) HO and/or (2) wound failure (defined as wounds requiring surgical débridement after definitive closure, or wounds that were not closed or covered within 21 days of injury) in patients sustaining combat wounds. METHODS: Two hundred combat wounded active-duty service members who sustained high-energy extremity injuries were prospectively enrolled between 2008 and 2012. Of these 200 patients, 189 had adequate followups to determine the presence or absence of HO, and 191 had adequate followups to determine the presence or absence of wound failure. In addition to injury-specific and demographic data, we quantified 24 cytokines and chemokines during each débridement. Patients were followed clinically for 6 weeks, and radiographs were obtained 3 months after definitive wound closure. Associations were investigated between these markers and wound failure or HO, while controlling for known confounders. RESULTS: The presence of an amputation (p < 0.001; odds ratio [OR], 6.1; 95% CI. 1.63-27.2), Injury Severity Score (p = 0.002; OR, 33.2; 95% CI, 4.2-413), wound surface area (p = 0.001; OR, 1.01; 95% CI, 1.002-1.009), serum interleukin (IL)-3 (p = 0.002; OR, 2.41; 95% CI, 1.5-4.5), serum IL-12p70 (p = 0.01; OR, 0.49; 95% CI, 0.27-0.81), effluent IL-3 (p = 0.02; OR, 1.75; 95% CI, 1.2-2.9), and effluent IL-13 (p = 0.006; OR, 0.67; 95% CI, 0.50-0.87) were independently associated with HO formation. Injury Severity Score (p = 0.05; OR, 18; 95% CI, 5.1-87), wound surface area (p = 0.05; OR, 28.7; 95% CI, 1.5-1250), serum procalcitonin ([ProCT] (p = 0.03; OR, 1596; 95% CI, 5.1-1,758,613) and effluent IL-6 (p = 0.02; OR, 83; 95% CI, 2.5-5820) were independently associated with wound failure. CONCLUSIONS: We identified associations between patients' systemic and local inflammatory responses and wound-specific complications such as HO and wound failure. However, future efforts to model these data must account for their complex, time dependent, and nonlinear nature. LEVEL OF EVIDENCE: Level II, prognostic study. See the Instructions for Authors for a complete description of levels of evidence.
Authors: Benjamin K Potter; Travis C Burns; Anton P Lacap; Robert R Granville; Donald A Gajewski Journal: J Bone Joint Surg Am Date: 2007-03 Impact factor: 5.284
Authors: Lori A Ehrlich; Ho Yeon Chung; Irene Ghobrial; Sun Jin Choi; Francesca Morandi; Simona Colla; Vittorio Rizzoli; G David Roodman; Nicola Giuliani Journal: Blood Date: 2005-05-05 Impact factor: 22.113
Authors: Jason S Hawksworth; Alexander Stojadinovic; Frederick A Gage; Doug K Tadaki; Philip W Perdue; Jonathan Forsberg; Thomas A Davis; James R Dunne; John W Denobile; Trevor S Brown; Eric A Elster Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: Edward R Utz; Eric A Elster; Douglas K Tadaki; Frederick Gage; Philip W Perdue; Jonathan A Forsberg; Alexander Stojadinovic; Jason S Hawksworth; Trevor S Brown Journal: J Surg Res Date: 2009-09-15 Impact factor: 2.192
Authors: Jonathan Agner Forsberg; Eric A Elster; Romney C Andersen; Eric Nylen; Trevor S Brown; Matthew W Rose; Alexander Stojadinovic; Kenneth L Becker; Francis Xavier McGuigan Journal: J Bone Joint Surg Am Date: 2008-03 Impact factor: 5.284
Authors: Jonathan Agner Forsberg; Joseph M Pepek; Scott Wagner; Kevin Wilson; James Flint; Romney C Andersen; Doug Tadaki; Frederick A Gage; Alexander Stojadinovic; Eric A Elster Journal: J Bone Joint Surg Am Date: 2009-05 Impact factor: 5.284
Authors: Nicola C Stein; Carmen Kreutzmann; Sara-Pia Zimmermann; Ute Niebergall; Lars Hellmeyer; Claudia Goettsch; Michael Schoppet; Lorenz C Hofbauer Journal: J Bone Miner Res Date: 2008-05 Impact factor: 6.741
Authors: Gabriel J Pavey; Ammar T Qureshi; Donald N Hope; Rebecca L Pavlicek; Benjamin K Potter; Jonathan A Forsberg; Thomas A Davis Journal: Clin Orthop Relat Res Date: 2015-09 Impact factor: 4.176
Authors: Ammar T Qureshi; Erica K Crump; Gabriel J Pavey; Donald N Hope; Jonathan A Forsberg; Thomas A Davis Journal: Clin Orthop Relat Res Date: 2015-09 Impact factor: 4.176
Authors: Amanda K Huber; Nicole Patel; Chase A Pagani; Simone Marini; Karthik R Padmanabhan; Daniel L Matera; Mohamed Said; Charles Hwang; Ginny Ching-Yun Hsu; Andrea A Poli; Amy L Strong; Noelle D Visser; Joseph A Greenstein; Reagan Nelson; Shuli Li; Michael T Longaker; Yi Tang; Stephen J Weiss; Brendon M Baker; Aaron W James; Benjamin Levi Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore Journal: Curr Osteoporos Rep Date: 2015-04 Impact factor: 5.096
Authors: Emilie Barruet; Blanca M Morales; Corey J Cain; Amy N Ton; Kelly L Wentworth; Tea V Chan; Tania A Moody; Mariëlle C Haks; Tom Hm Ottenhoff; Judith Hellman; Mary C Nakamura; Edward C Hsiao Journal: JCI Insight Date: 2018-11-15
Authors: Catherine R Thorpe; Serra Ucer Ozgurel; Laura C Simko; Richard Goldstein; Gabrielle G Grant; Chase Pagani; Charles Hwang; Kaetlin Vasquez; Michael Sorkin; Anita Vaishampayan; Jeremy Goverman; Robert L Sheridan; Jonathan Friedstat; John T Schulz; Jeffrey C Schneider; Benjamin Levi; Colleen M Ryan Journal: J Burn Care Res Date: 2019-06-21 Impact factor: 1.845
Authors: Keith A Alfieri; Benjamin K Potter; Thomas A Davis; Matthew B Wagner; Eric A Elster; Jonathan A Forsberg Journal: Clin Orthop Relat Res Date: 2015-09 Impact factor: 4.176
Authors: Gabriel J Pavey; Ammar T Qureshi; Allison M Tomasino; Cary L Honnold; Danett K Bishop; Shailesh Agarwal; Shawn Loder; Benjamin Levi; Maurizio Pacifici; Masahiro Iwamoto; Benjamin K Potter; Thomas A Davis; Jonathan A Forsberg Journal: Bone Date: 2016-06-28 Impact factor: 4.398